132 results about "Gamma-Tocopherol" patented technology

The present invention is generally related to the discovery of the therapeutic benefit of administering gamma-tocopherol and gamma-tocopherol derivatives. More specifically, the use of gamma-tocopherol and racemic LLU-alpha, (S)-LLU-alpha, or gamma-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.

The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol or a tocopherol such as alpha tocopherol, and an emulsifying agent.

The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the prevention of and treatment of neurological disorders. Dietary or parenteral administration of desmethyl tocopherols inhibits the undesired nitration of neurological components.

The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.

The present invention relates to compositions comprising DHA, EPA, LA and GLA. The compositions may further comprise other omega-3 PUFAs, MUFAs, SFAs, gamma tocopherol, Vitamin A and Vitamin B. The compositions are useful for treating neurologic disorders. The compositions are administered chronically for the prevention and / or treatment of multiple sclerosis (MS) and other degenerative diseases.

Disclosed herein is a method of preventing or retarding the progression of diabetic microvascular and macrovascular complications by chronically administering a therapeutically effective amount of gamma-tocopherol to a diabetic patient. It is further disclosed that a greater cytoprotective benefit is provided by administering a blend of gamma-tocotrienol and alpha-tocotrienol.

The invention relates to a method for separating single tocopherol from mixed tocopherol, which takes the mixed tocopherol with a content of 50 percent to 100 percent as a raw material and adopts a four-area simulated moving bed chromatography system to separate a d-alpha-tocopherol, a d-beta-tocopherol, a d-gamma-tocopherol and a d-delta tocopherol with the purity and yield all more than 98 percent. As the simulated moving bed chromatography separation is a continuous process, the method has the advantages of high degree of production automation, simple technique, high production efficiency, continuous production and stable product quality. As an adsorbent and a solvent have low consumption, the whole separating device does not relate to chemical reactions.

A uniform microfluidized nanoemulsion is disclosed containing a synergistic combination of two antioxidants and a cell membrane stabilizer phospholipid (i.e., an anti-oxidant synergy formulation; ASF). The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of typically cell-impermeant antioxidants (i.e., for example, tocopherol) and / or systemic bioavailability. As a nanoemulsion, synergistic combination has greater anticancer efficacy than the same combination applied as a free solution.

The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.

A novel method for improving the tissue quality of an animal is provided. The method comprises feeding the animal a diet supplemented with gamma-tocopherol in an amount effective to improve the tissue quality. The gamma-tocopherol may be fed alone or in combination with other antioxidants, such as alpha-tocopherol. The method may be practiced on ruminants and non-ruminants.

The present invention provides for compositions, medicaments, and methods for treating or alleviating the symptoms of dry eye syndrome or chronic dry eye. More specifically, the present embodiments provide for medicaments consisting of tocopherol or tocotrienol eyedrops. A single topical administration of tocopherol or tocotrienol eyedrops in the eyes of a subject suffering from dry eye alleviates symptoms for at least one day. In particular, the eyedrop medicament consists of α-tocopheryl acetate; α-tocopheryl acetate and about 0.5% aqueous component; or α-tocopheryl acetate, about 2.5% tocopherol emulsifier, and about 20% to about 30% aqueous excipient.

Disclosed is a process for the production of high purity alpha-tocotrienol from palm oil extract. More particularly, the invention relates to a process for the separation of alpha-tocotrienol from a mixtures of other tocotrienols and tocopherols and the use of a simplified separation scheme based on a combination of solid phase extraction and simulated moving bed (SMB) separation steps employing polar phase simulated moving bed operation. The process is useful for providing a continuous route and a simplified processing route to providing pure alpha-tocotrienol as a major product essentially free of other tocotrienols and tocopherols including: beta-tocopherol, gamma-tocotrienol, delta-tocotrienol, gamma-tocopherol, delta-tocopherol, front end and back end carotenoids, and alpha-tocopherol as a by-product from palm oil extract. Alpha-tocotrienol is a form of vitamin E and may be useful as a treatment for preventing stroke or reducing brain and nerve damage following a stroke.

A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal stent, and more specific beneficial applications is an endovascular stent, and the gamma-tocopherol elutes from a coating or carrier coupled with the stent. Certain combinations are provided with the des-methyl-tocopherol or phytyl substituted chromanol, e.g. gamma-tocopherol, combined with an additional agent such as an anti-restenosis agent, e.g. sirolimus, tacrolimus, everolimus, or paclitaxel, in order to provide synergistic benefit to tissues along the stented or recanalized regions. Other forms of tocopherol or tocotrienol, or other phytyl substituted chromanols, and other compounds such as palm oil, are also contemplated, for use to treat restenosis.

A pharmaceutical formulation comprising (a) 17-allylamino-17-demethoxy-geldanamycin; (b) an ester of d-α-tocopheryl succinate and polyethylene glycol; and (c) a pharmaceutically acceptable, water-miscible organic solvent.

The present invention is generally related to the discovery of the therapeutic benefit of administering gamma-tocopherol and gamma-tocopherol derivatives. More specifically, the use of gamma-tocopherol and racemic LLU-alpha, (S)-LLU-alpha, or gamma-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.

The present invention provides a method of preventing or treating a disease caused by oxidation in vivo by administering a pharmacologically effective amount of at least one compound selected from the group consisting of: (1) 2,5,7,8-tetramethyl-2-(beta-carboxyethyl)-6-hydroxychromane; and (2) 2,7, 8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychromane. Further, it provides use of a compound selected from the group consisting of (3) alpha-tocopherol, (4) alpha-tocotrienol, (5) gamma-tocopherol and (6) gamma-tocotrienol for generation in vivo of any of the above compounds (1) and (2) to treat a disease caused by oxidated low density lipoprotein (LDL).

The invention discloses a method for preparing natural alpha tocopherol and mixing tocopherol by a one-step method, which relates to the technical field of separation and extraction in bioengineering. The method comprises the following steps: performing esterification of plant oil deodorizer distillate; washing; dissolving and filtering tocopherol; adsorbing a fluidized bed of a tocopherol solution by resin; dynamically absorbing a tocopherol adsorption waste liquid by resin; desorpting, and performing molecular distillation to obtain the alpha tocopherol and mixing tocopherol. According to the invention, no organic solvent is used for the alpha tocopherol, and alpha tocopherol has the advantages of environmental protection and safety, and has the characteristics of green and health by comparing with the alpha tocopherol prepared by a traditional method; and the produced mixing tocopherol has the characteristics of high quality, high yield, low cost, and easy batch production.

The present invention is directed to a method of synthesizing a compound of Formula I: the method comprising oxidizing alpha-tocopherol with a metal salt oxidizing agent to form the compound of Formula I, wherein the stoichiometric ratio (mol / mol) of metal salt oxidizing agent / alpha-tocopherol is 1.6 to 4. The invention is also directed to a method of synthesizing a compound of Formula I, the method comprising (a) hydrolyzing alpha-tocopheryl acetate in the presence of a base; (b) neutralizing the hydrolyzing of (a), thereby forming alpha-tocopherol; and (c) oxidizing the alpha-tocopherol of I (b) with a metal salt oxidizing agent to form the compound of Formula I, wherein the stoichiometric ratio (mol / mol) of metal salt oxidizing agent / aipha-tocopherol is 1.6 to 4.

Disclosed is a process for the production of high purity alpha-tocotrienol from palm oil extract. More particularly, the invention relates to a process for the separation of alpha-tocotrienol from a mixtures of other tocotrienols and tocopherols and the use of a simplified separation scheme based on a combination of solid phase extraction and simulated moving bed (SMB) separation steps employing polar phase simulated moving bed operation. The process is useful for providing a continuous route and a simplified processing route to providing pure alpha-tocotrienol as a major product essentially free of other tocotrienols and tocopherols including: beta-tocopherol, gamma-tocotrienol, delta-tocotrienol, gamma-tocopherol, delta-tocopherol, front end and back end carotenoids, and alpha-tocopherol as a by-product from palm oil extract. Alpha-tocotrienol is a form of vitamin E and may be useful as a treatment for preventing stroke or reducing brain and nerve damage following a stroke.

The invention discloses a kit for bisulfite conversion of free DNA. The kit comprises a bisulfite solution, a protective solution, washing liquor A, a magnetic bead suspension, washing liquor B, washing liquor C and eluate, wherein the protective solution is prepared from the following ingredients: 80% to 85% of tetrahydrofuran furfuryl alcohol, 10% to 15% of D-alpha tocopherol cetomacrogol 1000 succinate, 0.2% to 0.3% of tetrahydroglycosyl acetate, 0.05% to 0.1% of ethoxychrysoidine and the balance of water. The invention further provides a method for bisulfite conversion and DNA purificationof the free DNA by using the kit. According to the kit, a sulfite conversion method is subjected to great technological improvement, so that ctDNA conversion can be completed rapidly (40 to 60 minutes) under mild conditions (70 DEG C to 80 DEG C), pH of a system can be stabilized, ctDNA degradation is prevented, high-conversion-ratio, high-quality and high-purity free DNA can be rapidly obtained,and full automated operation of methylation researches is facilitated.

A therapy for decreasing the rate of demyelination in multiple sclerosis comprising administering gamma-tocopherol and / or gamma-tocotrienol in a therapeutically effective dosage. The therapeutic dosage is high, between about 800 mg to about 10 grams of gamma-tocopherol and between about 50 mg to about 5 grams of gamma-tocotrienol per day.

The present invention relates to a skin preparation for external application, comprising a tocopherol aminoalkylcarboxylate ester having no substituent on the N atom and / or a salt thereof. Preferable tocopherol aminoalkylcarboxylate in the present invention is one or more compound selected from α-tocopherol derivatives, β-tocopherol derivatives, γ-tocopherol derivatives and δ-tocopherol derivatives. The present invention also relates to a cosmetic material comprising the skin preparation.

The invention discloses a repairing and whitening composition and a preparation method thereof. The repairing and whitening composition contains acetyl chitosamine, glabridin, hydrogenated lecithin, butyl methoxydibenzoylmethane, tocopherol, piperine, dipotassium glycyrrhizinate, potassium methoxysalicylate, tranexamic acid, alpha-arbutin, nicotinamide, a camellia extract and 3-o-ethyl ascorbic acid. According to the whitening action mechanism, the whitening effect is enhanced in an oriented multi-target multi-way mode, and butyl methoxydibenzoylmethane resists ultraviolet damage; dipotassiumglycyrrhizinate and acetyl chitosamine have the effects of reducing inflammation and ultraviolet stimulation; arbutin and glabridin inhibit tyrosinase activity; tocopherol inhibits tyrosine from beingoxidized into dopa; 3-o-ethyl ascorbic acid reduces dopaquinone into dopa; glabridin inhibits the activity of dopa pigment tautomerase and the activity of DHICA oxidase; tranexamic acid and nicotinamide inhibit melanin transport; nicotinamide and potassium-4-methoxysalicylate promote epidermis renewal; and eight target points act together and coordinate with each other to achieve the whitening effect.

This invention relates to methods to reduce or lipid peroxidation and diminish free radical damage in a human, resulting in reduced blood levels of dityrosine, isoprostane, and placental growth factor thus preferably preventing or reducing cardiovascular disease by the in humans administration of compositions comprised of sesame lignans and ‘gamma tocopherol to humans.

The present invention discloses a vehicle rubber sealing strip, which comprises, by weight, an ethylene-propylene-diene monomer, paraffin oil, calcium carbonate, talc powder, a dispersant, an anti-ultraviolet agent, an antioxidant, an anti-scorching agent CTP, a foaming agent, a nitrogen-free vulcanizing agent, an auxiliary vulcanizing agent, a terpene resin, zinc borate powder, phosphate, and alpha-tocopherol. The low-harm and toxicity-free vehicle sealing strip has characteristics of environmental pollution reducing and reasonable cost maintaining.

Described herewithin is a composition comprising an anti-chafing balm with C18-36 acid triglycerides, capric / carprylic triglycerides, and tribehinin together with a chelated silver oxide complex comprising a barrier film when applied to the skin. The film is a dual purpose antibacterial and anti-chafing barrier topically applied to human skin, providing a layer of chelated silver oxide complex further comprised of a dermatologically acceptable carrier, with friction (chafe) reducing properties, selected from the group consisting of organic solutions, gels, liquids, balms, aerosols, emulsifiers, lotions, water-in-oil emulsions, oil-in-water emulsions, surfactants, aloe barbedensis leaf juice and tocopherol acetate.

The invention discloses a mild and moist facial cleanser which is prepared from the following components in parts by weight: 0.1-15 parts of glycerinum, 0.1-20 parts of butanediol, 0.05-1 part of PCA sodium, 1-5 parts of glycol distearate, 2-5 parts of cocamidopropyl betaine, 5-10 parts of lauramidopropyl betaine, 0.5-1 part of papain, 5-10 parts of hydrolyzed collagen, 5-9 parts of a milk protein extract, 1-3 parts of a pansy extract, 1-3 parts of a honey extract, 1-5 parts of EDTA disodium, 0.5-1 part of citric acid, 0.5-1 part of sodium citrate, 1-3 parts of tocopherol, 0.5-1 part of phenoxyethanol, 0.5-1 part of hyaluronic acid, 0.5-3 parts of an essence and the balance of water.

The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol or a tocopherol such as alphatocopherol, and an emulsifying agent.

A whole-length cDNA sequence of gamma-tocopherol methyltransferase (gamma-TMT) cloned from the Brassica oleracea L.Var, capitata L. is disclosed. The gamma-TMT and its coding gene are also disclosed. The prokaryotic expression plasmid, plant constitution and specific expression plasmid in plant seed are configured. After said gamma-TMT structure gene is transferred to high-expression microbes, a biocatalytic method is used to methylate the gamma-tocopherol to obtain alpha-tocopherol and the transgenic plant with high content of alpha-tocopherol.